European study reveals Parkinson’s cost society nearly €23 billion in a single year

A major study led by the European Academy of Neurology has revealed the true scale of the financial impact of Parkinson’s across Europe, calculating that the condition cost European society a staggering 22.8 billion euros in 2019 alone. Adjusted for inflation, that figure reaches 28.8 billion euros at 2025 prices, illustrating the immense pressure placed on healthcare systems, families, and communities. Published in the journal Movement Disorders as part of the Cost of Illness in Neurology in Europe project, the research evaluated data across forty-seven European nations. Researchers estimated that roughly 2.2 million adults were living with Parkinson’s in 2019. With an ageing population alongside earlier and more accurate diagnoses, the prevalence across Europe has almost doubled since 1990, jumping from 135 to 247 cases per 100,000 people. This makes it the fastest growing neurodegenerative condition in the world. Where exactly does all that money go? The lion’s share, about 76 percent or 17.3 billion euros, goes towards direct medical and practical support. This includes hospital stays, consultations, prescription medications, professional social care, and essential home adaptations. Crucially, the study also places a hard number on the invisible work done at home. Unpaid informal care provided by family members, partners, and friends accounted for 4.4 billion euros, which represents almost a fifth of the total economic footprint. Anyone managing life with Parkinson’s knows that family caregivers are the real backbone of day to day support, and this research formally recognizes that massive contribution. An additional 1 billion euros was attributed to indirect costs, primarily through lost workplace productivity when people or their partners have to reduce their working hours. Looking across the map, five countries accounted for three quarters of the entire European financial total. Germany topped the list at 5.7 billion euros, followed closely by France at 5.3 billion euros, Italy at 2.6 billion euros, Spain at 1.9 billion euros, and the United Kingdom at 1.6 billion euros. According to Professor Richard Dodel from the University of Duisburg-Essen, this heavy concentration in Western Europe does not mean other nations are unaffected. Rather, it reflects larger populations, higher proportions of older adults, higher overall healthcare spending, and much better local data collection. In fact, the researchers highlighted substantial data gaps across the continent. Out of fourteen eligible economic studies available for analysis, thirteen came exclusively from high income nations. Because zero primary cost data existed for lower middle income European countries, the economic calculation could only cover forty-three of the forty-seven countries surveyed. Professor Günther Deuschl, founding president of the European Academy of Neurology, stressed that putting concrete numbers to the condition gives policymakers and health services the hard evidence they need to plan ahead properly. Having robust data makes it far harder for governments to overlook the urgent need for specialist neurological care, community resources, and long overdue support for unpaid carers.